Lupin is currently the fifth-largest generic pharmaceutical company in the U.S. by prescriptions dispensed, with 5.5% generic market share, according to IMS Health.
Lupin's journey began in 2003 with three Baltimore-based employees and Lupin's first U.S. generic product approval. As a market share leader in 44 generic products and among the top three in 79 products in the U.S., Lupin now markets a total of 124 products, according to IMS Health.
Last fiscal year, Lupin generated over $887 million in net revenues, contributing 43% of the company's global revenues.
In March of this year, Lupin completed its acquisition of privately held U.S.-based Gavis Pharmaceuticals LLC and Novel Laboratories Inc. Novel has since been renamed Lupin Somerset. The Gavis-Novel acquisition positions Lupin as having the fifth-largest pipeline of ANDA (Abbreviated New Drug Application) filings with the Food and Drug Administration. Lupin notes that it has brought significant, high-quality, affordable medications to the marketplace, which has helped fuel the growth of the company's business.
Today, Lupin has 45 first-to-file products, which include 25 exclusive FTF opportunities.
The momentum of Lupin's sustained growth year over year is a result of a valuable pipeline, solid customer relationships and smooth execution. Lupin has 163 ANDAs pending FDA approval and a deep pipeline of products under development for the U.S.
Lupin has a strong corporate culture of excellence in place, ensuring strict adherence to FDA regulations year after year.
Last fiscal year, Lupin launched 21 new products, including the successful commercialization of the exclusive generic equivalent of Glumetza. The majority of Lupin's products are vertically integrated, which ensures quality control throughout each step of product development and manufacturing. This gives Lupin an unparalleled advantage over its competitors, the company points out, as it is able to control its supply chain while offering competitive pricing.
Recent generic launches include diclofenac topical solution, 1.5% (Pennsaid 1.5%); norgestimate and ethinyl estradiol tablets (Ortho Tri-Cyclen); Blisovi Fe 1.5/30 tablets (Loestrin Fe 1.5/30); Blisovi Fe 1/20 tablets (Loestrin Fe 1/20); and zolpidem tartrate sublingual, CIV tablets (Intermezzo).
Lupin aims to continue to strengthen its market presence by launching new products and expanding its pipeline to offer medications in such new therapeutic areas as dermatology, pediatrics, women's health, inhalation and complex injectables.
Lupin says its steadfast commitment to quality and reliability has resulted in the company consistently delivering high-quality products, and its ongoing investment in technological capabilities will position the company to ensure customer satisfaction for years to come.
111 South Calvert St.
Baltimore, Md. 21202
Key contact: BOB HOFFMAN
Executive Vice President, U.S. Generics
Phone: (410) 576-2000
LUPIN'S RECENT GENERIC LAUNCHES BRAND EQUIVALENT Diclofenac Topical Solution 1.5% Pennsaid 1.5% Norgestimate/Ethinyl Estradiol Tablets Ortho Tri-Cyclen Blisovi Fe 1.5/30 Tablets Loestrin Fe 1.5/30 Blisovi Fe 1/20 Tablets Loestrin Fe 1/20 Zolpidem Tartrate Sublingual CIV Tablets Intermezzo